FierceBiotech17h
AHA 2024: Boston Scientific, Abbott tout long-term heart occluder data
Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...
MassDevice18h
Abbott reports positive Amplatzer Amulet data in head-to-head trial with Boston Scientific’s Watchman
Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.
GlobalData on MSN23h
Abbott’s Amplatzer Amulet shows promise in atrial fibrillation trial
Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...
Medpage Today on MSN1d
More Lp(a)-Reducing Tx; Cardiac Denervation for Afib; LAA Occluders at 5 Years
Among patients undergoing isolated coronary artery bypass grafting, partial cardiac denervation helped reduce the risk of postoperative atrial fibrillation (Afib) in a randomized trial. (JAMA ...
TCTMD1d
OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain
Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.
MedPage Today1d
Left Atrial Appendage Closure Reduced Bleeding After Afib Ablation
Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...